USPTO Speeds Up Patent Appeals, Cutting Wait Times in Half
Published Date: 5/6/2026
Notice
Summary
The USPTO is extending its Fast-Track Appeals Pilot Program until May 6, 2028, letting inventors speed up their patent appeal reviews. Now, decisions will come even faster—within four months instead of six! This helps inventors get answers quicker without changing fees, making the patent process smoother and snappier.
Analyzed Economic Effects
4 provisions identified: 2 benefits, 2 costs, 0 mixed.
Fast-Track Program Extended to 2028
If you have a docketed ex parte appeal before the Patent Trial and Appeal Board, the USPTO is extending the Fast-Track Appeals Pilot Program so it will accept petitions to advance appeals out of turn through May 6, 2028. The program is effective beginning May 6, 2026 and will run until May 6, 2028.
Decision Time Cut to Four Months
Effective in this extension, the Fast-Track Appeals Pilot Program sets a new target of reaching a decision on each ex parte appeal within four months from the date the appeal enters the program, instead of the prior six-month target.
Quarterly Cap on Granted Fast-Track Petitions
The program continues to limit the number of granted Fast-Track petitions to 125 granted petitions per quarter; there is no longer an overall 500-petition total cap. If a quarterly limit is reached, the PTAB retains flexibility to accept additional petitions for that or the next quarter.
Petition Requires Paying Specified Fee
To participate in the Fast-Track Appeals Pilot Program, appellants must file a petition under 37 CFR 41.3 and pay the petition fee specified in 37 CFR 41.20(a) when submitting a Fast-Track petition.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-16744, Request for Comments on Community Outreach Office Locations in the Southwest States
The USPTO wants your ideas on where to open new community outreach offices in the Southwest states like Arizona and Texas. These offices will help inventors, small businesses, and students get better support with patents. Share your thoughts by September 16, 2026, so the USPTO can pick the best spots and keep innovation booming without extra costs to you!
2026-16315, Administrative Updates to the General Requirements Bulletin for Admission to the Examination for Registration To Practice in Patent Cases Before the United States Patent and Trademark Office
Starting August 11, 2026, the USPTO is upgrading Biomedical Science degrees from Category B to Category A for patent bar eligibility. This means more people with this degree can now take the patent exam and become patent practitioners. No extra fees or delays—just a smoother path for those with the right science background to join the patent world!
2026-14941, Grant of Interim Extension of the Term of U.S. Patent No. 8,461,196; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means they keep exclusive rights to the drug until July 25, 2027, giving them more time to sell it without competition. This extension helps the company protect their investment while the drug gets final approval.
2026-14939, Grant of Interim Extension of the Term of U.S. Patent No. 8,877,798; Centanafadine Hydrochloride
Otsuka America Pharmaceutical got a one-year extra patent life for their drug centanafadine hydrochloride because the FDA review is still going on. This means their patent, which was set to expire on July 25, 2026, now lasts until July 25, 2027. This extension helps Otsuka keep exclusive rights to their drug a bit longer while waiting for final FDA approval.
2026-14793, Requirement To Identify All Real Parties in Interest to a Third Party Request for an Ex Parte Reexamination
The USPTO wants anyone asking for a third-party ex parte reexamination to clearly say who’s really behind the request. This helps stop sneaky tricks and keeps the process honest. If you’re involved, get ready to share this info confidentially by August 21, 2026, or risk delays or issues.
2026-14388, Agency Information Collection Activities; Submission to the Office of Management and Budget for Review and Approval; Comment Request; Admission to Practice and Roster of Registered Patent Attorneys and Agents Admitted to Practice Before the United States Patent and Trademark Office
The USPTO is asking for public feedback on its paperwork rules for patent attorneys and agents who want to practice before the office. This helps keep the process smooth and fair without making people fill out too many forms. If you have thoughts, send them in by August 17, 2026—no fees or big changes are happening right now, just a review.
Previous / Next Documents
Previous: 2026-08797, Self-Regulatory Organizations; Financial Industry Regulatory Authority, Inc.; Notice of Filing of Amendment No. 1 and Order Instituting Proceedings To Determine Whether To Approve or Disapprove a Proposed Rule Change, as Modified by Amendment No. 1, To Adopt FINRA Rule 3290 (Outside Activities Requirements)
FINRA wants to update its rules about what outside jobs and activities financial workers can have. This new rule, FINRA Rule 3290, replaces two older rules to make things clearer and easier to follow. If approved, it affects financial pros who must report outside work, with no big cost changes but tighter reporting rules coming soon.
Next: 2026-08799, Certain Nanolaminate Alloy Coated Metal Parts and Products Containing the Same; Notice of Request for Submissions on the Public Interest
The U.S. International Trade Commission is asking the public and government agencies to share their thoughts on a possible ban of certain nanolaminate alloy coated metal parts and products. This affects companies like Parker Hannifin and others who import or sell these products in the U.S. If the ban happens, it could change what products are allowed in and might impact businesses and consumers soon.